Compile Data Set for Download or QSAR
maximum 50k data
Found 424 Enz. Inhib. hit(s) with all data for entry = 2108
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352621((R)-tert-butyl (2-(2- (oxazolidin-3-yl)-2- oxoethy...)
Affinity DataIC50:  1.96nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352909(US10745364, Example 115B | US9809561, 115A)
Affinity DataIC50:  2.03nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352646((S)-neopentyl (2-(2- (methylamino)-2- oxoethyl)-4-...)
Affinity DataIC50:  2.11nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352591((S)-methyl 2-(6-((tert- butoxycarbonyl)amino)-4-((...)
Affinity DataIC50:  2.15nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352589((S)-methyl 2-(6-((tert- butoxycarbonyl)amino)-4-((...)
Affinity DataIC50:  2.24nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352725(US10745364, Example 49 | US9809561, 49 | tert-buty...)
Affinity DataIC50:  2.46nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352638((S)-methyl 3-(2-(6-((tert- butoxycarbonyl) amino)-...)
Affinity DataIC50:  2.53nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352645((S)-tert-butyl (2-(2- (oxazolidin-3-yl)-2- oxoethy...)
Affinity DataIC50:  2.56nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352512((S)-1,1,1-trifluoro-2-methylpropan-2-yl (4-((4-flu...)
Affinity DataIC50:  2.72nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352785((S)-tert-butyl (2-((2H-1,2,3-triazol-2- yl)methyl)...)
Affinity DataIC50:  2.78nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352784((S)-tert-butyl (2-((1H-1,2,3-triazol-1- yl)methyl)...)
Affinity DataIC50:  2.80nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352619((S)-tert-butyl (4-((3-chloro-4- fluorophenyl) sul...)
Affinity DataIC50:  2.81nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352481((R)-tert-butyl (2-(hydroxymethyl)-4-((3-(trifluoro...)
Affinity DataIC50:  3.01nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352537((S)-1,1,1-trifluoro-2-methylpropan-2-yl (4-((3,4-d...)
Affinity DataIC50:  3.04nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352782((S)-tert-butyl (2-((1H-1,2,4-triazol-1- yl)methyl)...)
Affinity DataIC50:  3.04nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352849(US10745364, Example 92 | US9809561, 92)
Affinity DataIC50:  3.11nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352748((S)-tert-butyl (2-(2-acetamido-2- methylpropyl)-4-...)
Affinity DataIC50:  3.13nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352590((S)-methyl 2-(6-((tert- butoxycarbonyl)amino)-4-((...)
Affinity DataIC50:  3.13nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352552((R)-tert-butyl (2-((pyridin-2-ylsulfonyl)methyl)-4...)
Affinity DataIC50:  3.28nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352821(1,1,1-trifluoro-2-methylpropan-2-yl ((R or S)-4-((...)
Affinity DataIC50:  3.33nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352744((R)-1,1,1-trifluoro-2-methylpropan-2-yl (2-(2-(2-o...)
Affinity DataIC50:  3.42nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352908(2,2,2-trifluoro-1,1- dimethylethyl (1-{[2- (triflu...)
Affinity DataIC50:  3.46nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352746((S)-tert-butyl (2-(2-acetamido-2-methylpropyl)-4-(...)
Affinity DataIC50:  3.49nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352775(US10745364, Example 58 | US9809561, 58 | tert-buty...)
Affinity DataIC50:  3.56nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352613((S)-tert-butyl (2-(2- amino-2-oxoethyl)-4- ((3-(tr...)
Affinity DataIC50:  3.66nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352588((S)-methyl 2-(6-((tert-butoxycarbonyl)amino)-4-((3...)
Affinity DataIC50:  3.76nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352629((S)-tert-butyl (2-(2- oxo-2-((pyrazolo[1,5- a]pyri...)
Affinity DataIC50:  3.79nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352558((R)-tert-butyl (2- ((methylsulfonyl)methyl)-4-((3-...)
Affinity DataIC50:  3.86nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352905(2,2,2-trifluoro-1,1- dimethylethyl {l-[(3- chloro-...)
Affinity DataIC50:  3.87nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352612((S)-tert-butyl (2-(2- amino-2-oxoethyl)-4- ((4-flu...)
Affinity DataIC50:  3.89nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352540((S)-1,1,1-trifluoro-2-methylpropan-2-yl (4-((3-chl...)
Affinity DataIC50:  3.92nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352544((S)-1,1,1-trifluoro-2-methylpropan-2-yl (4-((2-met...)
Affinity DataIC50:  3.93nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352755((S)-1,1,1-trifluoro-2-methylpropan-2-yl (2-(2-acet...)
Affinity DataIC50:  3.99nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352729((S)-tert-butyl (2-(2-propionamidoethyl)-4- ((3-(tr...)
Affinity DataIC50:  4.07nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352700((S)-(2-(2-(methoxyamino)-2-oxoethyl)-4-((3-(triflu...)
Affinity DataIC50:  4.07nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352752((R)-tert-butyl (2-(2-acetamido-2- methylpropyl)-4-...)
Affinity DataIC50:  4.09nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352545((R)-tert-butyl (2-((pyridin-2-ylthio)methyl)-4-((3...)
Affinity DataIC50:  4.13nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352644((S)-tert-butyl (2-(2-(ethylamino)-2- oxoethyl)-4-...)
Affinity DataIC50:  4.16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352552((R)-tert-butyl (2-((pyridin-2-ylsulfonyl)methyl)-4...)
Affinity DataIC50:  4.16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352758((S)-1,1,1-trifluoro-2-methylpropan-2-yl (2-(2-acet...)
Affinity DataIC50:  4.17nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352906(2,2,2-trifluoro-1,1- dimethylethyl (1-{[1-ethyl- 3...)
Affinity DataIC50:  4.19nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352499(US10745364, Example 9 | US9809561, 9)
Affinity DataIC50:  4.23nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352733((S)-tert-butyl (2-(2-acetamidoethyl)-4-((3- (trifl...)
Affinity DataIC50:  4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352643((S)-tert-butyl (2-(2-oxo-2- (propylamino) ethyl)-...)
Affinity DataIC50:  4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352630((S)-tert-butyl (2- (2-(((1-ethyl-1H- pyrazol-3-yl)...)
Affinity DataIC50:  4.47nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352918(US10745364, Example 119 | US9809561, 119)
Affinity DataIC50:  4.49nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352859((S)-1,1,1-trifluoro-2- methylpropan-2-yl (2-(2-cya...)
Affinity DataIC50:  4.52nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352757((S)-1,1,1-trifluoro-2-methylpropan-2-yl (4-((4-flu...)
Affinity DataIC50:  4.52nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352484(US10745364, Example 2C | US9809561, 2C | [(R)-4-(3...)
Affinity DataIC50:  4.57nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM352789( tert-butyl (2-(2-hydroxy-2-methylpropyl)-4-((3-(t...)
Affinity DataIC50:  4.57nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 424 total ) | Next | Last >>
Jump to: